x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001104
| Product Information | |
|---|---|
| Product Name | Human Galanin Antibody Pair - BSA and Azide free |
| Species | Mouse; Rat |
| Description | The Antibody Pair can be used to quantify Human Galanin. BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Both capture and detector antibodies are rabbit monoclonal antibodies delivering consistent, specific, and sensitive results. |
| Detection Range | 4.688 pg/mL - 300 pg/mL |
| Precision | Intra-assay precision CV ≤ 10.0%; Inter-assay precision CV ≤ 10.0% |
| Target Information | |
|---|---|
| Target Name | GAL |
| UniProt No. | P22466 |
| Gene ID | 51083 |
| Target Description | Contracts smooth muscle of the gastrointestinal and genitourinary tract, regulates growth hormone release, modulates insulin release, and may be involved in the control of adrenal secretion. |
| Alternative Names | GAL; GAL 1; GAL GMAP; GAL1; GALA_HUMAN; Galanin message associated peptide; Galanin message-associated peptide; Galanin precursor; Galanin prepropeptide; Galanin related peptide; Galanin/GMAP prepropeptide; GALN; GLNN; GMAP; MGC40167 |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
